CL2008003730A1 - Derivado de metastina ; profarmaco de dicho derivado; producto farmaceutico de dicho derivado; uso de dicho derivado para tratar metastasis de cancer o crecimiento del cancer. - Google Patents

Derivado de metastina ; profarmaco de dicho derivado; producto farmaceutico de dicho derivado; uso de dicho derivado para tratar metastasis de cancer o crecimiento del cancer.

Info

Publication number: CL2008003730A1
Authority: CL; Chile
Prior art keywords: derivative; prodrug; metastin; pharmaceutical product; derived
Prior art date: 2004-06-25

Application number

CL2008003730A

Other languages

English (en)

Spanish (es)

Inventor

Kitada Chieko

Asami Taiji

Nishizawa Naoki

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-25

Filing date

2008-12-15

Publication date

2009-05-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003730(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-15 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2009-05-04 Publication of CL2008003730A1 publication Critical patent/CL2008003730A1/es

Links

KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 title abstract 3
206010027476 Metastases Diseases 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
230000005907 cancer growth Effects 0.000 title abstract 2
230000009401 metastasis Effects 0.000 title abstract 2
239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
229940127557 pharmaceutical product Drugs 0.000 title abstract 2
239000000651 prodrug Substances 0.000 title abstract 2
229940002612 prodrug Drugs 0.000 title abstract 2
102000013599 Kisspeptins Human genes 0.000 title 1
108010012048 Kisspeptins Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)

CL2008003730A 2004-06-25 2008-12-15 Derivado de metastina ; profarmaco de dicho derivado; producto farmaceutico de dicho derivado; uso de dicho derivado para tratar metastasis de cancer o crecimiento del cancer. CL2008003730A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2004187671		2004-06-25
JP2004363311		2004-12-15

Publications (1)

Publication Number	Publication Date
CL2008003730A1 true CL2008003730A1 (es)	2009-05-04

Family

ID=34971534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2008003730A CL2008003730A1 (es)	2004-06-25	2008-12-15	Derivado de metastina ; profarmaco de dicho derivado; producto farmaceutico de dicho derivado; uso de dicho derivado para tratar metastasis de cancer o crecimiento del cancer.

Country Status (20)

Country	Link
US (2)	US7625869B2 (fr)
EP (2)	EP2113513B1 (fr)
JP (3)	JP4346650B2 (fr)
CN (2)	CN101863971A (fr)
AR (1)	AR049938A1 (fr)
AU (1)	AU2005257484A1 (fr)
BR (1)	BRPI0512397A (fr)
CA (1)	CA2571420A1 (fr)
CL (1)	CL2008003730A1 (fr)
CR (1)	CR8828A (fr)
IL (1)	IL179640A0 (fr)
MA (1)	MA28903B1 (fr)
MX (1)	MXPA06014206A (fr)
NO (1)	NO20065957L (fr)
NZ (1)	NZ552029A (fr)
PE (2)	PE20060371A1 (fr)
RU (1)	RU2006145886A (fr)
SG (1)	SG153865A1 (fr)
TW (1)	TW200607816A (fr)
WO (1)	WO2006001499A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1494732B1 (fr)	2002-03-20	2008-01-30	MannKind Corporation	Appareil d'inhalation
AU2003292696A1 (en)	2002-12-26	2004-08-10	Takeda Pharmaceutical Company Limited	Metastin derivative and use thereof
EP1604682A4 (fr)	2003-03-12	2009-06-24	Takeda Chemical Industries Ltd	Agents ameliorant la fonction gonadique
AU2005245338B2 (en)	2004-04-08	2011-11-17	Biomatrica, Inc.	Integration of sample storage and sample management for life science
MXPA06014206A (es)	2004-06-25	2007-02-14	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos.
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
AU2006290227B2 (en)	2005-09-14	2012-08-02	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
TWI386417B (zh) *	2005-12-22	2013-02-21	Takeda Pharmaceutical	轉移抑素衍生物及其用途
US8404643B2 (en) *	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20090093615A1 (en) *	2005-12-22	2009-04-09	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
US8183212B2 (en) *	2006-04-26	2012-05-22	Kyoto University	Compound having GPR54 agonistic activity
ITMI20061607A1 (it) *	2006-08-09	2008-02-10	Maria Vincenza Carriero	Peptidi con attivita farmacologica
TWI404726B (zh) *	2006-10-25	2013-08-11	Takeda Pharmaceutical	腫瘤轉移抑制素衍生物及其用途
CN101528772B (zh) *	2006-10-25	2013-03-13	武田药品工业株式会社	Metastin衍生物及其用途
EP2277900A4 (fr) *	2008-04-24	2011-08-03	Takeda Pharmaceutical	Dérivé de métastine et son utilisation
EP2275433B1 (fr) *	2008-04-30	2017-06-07	Kyoto University	Dérivé de metastine et son utilisation
SG10201507036TA (en)	2008-06-13	2015-10-29	Mannkind Corp	A dry powder inhaler and system for drug delivery
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
EP2609954B1 (fr)	2008-06-20	2021-12-29	MannKind Corporation	Appareil interactif pour l'établissement en temps réel d'un profil des efforts d'inhalation
US20110212890A1 (en) *	2008-07-30	2011-09-01	Takeda Pharmaceutical Company Limited	Metastin derivative and use thereof
CA2748517A1 (fr) *	2008-12-29	2010-07-08	Takeda Pharmaceutical Company Limited	Agent prophylactique/therapeutique pour le cancer
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US8716228B2 (en)	2009-05-27	2014-05-06	Yeda Research And Development Co. Ltd.	GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
UY33127A (es)	2009-12-22	2011-07-29	Takeda Pharmaceutical	Formulación de liberación sostenida
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
WO2012018638A2 (fr)	2010-07-26	2012-02-09	Biomatrica, Inc.	Compositions de stabilisation d'adn, d'arn, de protéines dans le sang et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
WO2012018639A2 (fr)	2010-07-26	2012-02-09	Biomatrica, Inc.	Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
EP2694402B1 (fr)	2011-04-01	2017-03-22	MannKind Corporation	Emballage coque pour cartouches pharmaceutiques
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
US9127038B2 (en)	2011-08-04	2015-09-08	Merck Sharp & Dohme Corp.	Kisspeptide-pentasaccharide conjugates
HK1200318A1 (en)	2011-10-24	2015-08-07	曼金德公司	Methods and compositions for treating pain
JP2015511600A (ja)	2012-03-14	2015-04-20	イェダリサーチアンドディベロップメントカンパニーリミテッド	修飾キスペプチンペプチドおよびその使用
EP2872205B1 (fr)	2012-07-12	2017-02-08	MannKind Corporation	Systèmes de libération de médicament en poudre sèche
EP3249054A1 (fr)	2012-12-20	2017-11-29	Biomatrica, INC.	Formulations et procédés pour stabiliser des réactifs pcr
JP6143270B2 (ja) *	2013-01-31	2017-06-07	学校法人東京薬科大学	マイオスタチン阻害ペプチド
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
US10220069B2 (en) *	2014-01-22	2019-03-05	The Johns Hopkins University	Compositions and methods for treating diabetes
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
WO2015191632A1 (fr)	2014-06-10	2015-12-17	Biomatrica, Inc.	Stabilisation de thrombocytes à des températures ambiantes
KR102589056B1 (ko)	2015-12-08	2023-10-12	바이오매트리카 인코포레이티드	적혈구 침강 속도의 감소
MA46353A (fr)	2016-09-30	2019-08-07	Myovant Sciences Gmbh	Méthodes de traitement de l'infertilité féminine
CN109206481B (zh)	2017-07-05	2023-08-18	尚华医药科技(江西)有限公司	一种肽类化合物、其应用及含其的组合物
CN108752233B (zh) *	2018-07-18	2020-10-16	河北师范大学	小分子凝胶因子、凝胶材料及制备方法和应用
CN115515937A (zh) *	2020-05-08	2022-12-23	范因斯坦医学研究院	用于合成肽模拟物的二聚体
WO2025217074A1 (fr)	2024-04-08	2025-10-16	Radionetics Oncology, Inc.	Agents thérapeutiques ciblant le récepteur de la kisspeptine (kiss1r) et leurs utilisations

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1524747A (en) *	1976-05-11	1978-09-13	Ici Ltd	Polypeptide
FR2488253A1 (fr) *	1980-08-08	1982-02-12	Roques Bernard	Nouveaux peptides et leur application en therapeutique
IL74827A (en) *	1984-05-21	1989-06-30	Salk Inst For Biological Studi	Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es) *	1990-08-24	1992-04-01	Syntex Inc	Antagonistas de la bradiquinina
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
AU7333496A (en)	1995-10-19	1997-05-07	Takeda Chemical Industries Ltd.	Quinoline derivatives as gnrh antagonists
JPH09169735A (ja)	1995-10-19	1997-06-30	Takeda Chem Ind Ltd	キノリン誘導体、その製造法および用途
AU2382097A (en)	1996-04-19	1997-11-12	Novo Nordisk A/S	Compounds with growth hormone releasing properties
CA2283299A1 (fr)	1997-03-07	1998-09-11	Human Genome Sciences, Inc.	186 nouvelles proteines secretees
JP4486187B2 (ja)	1998-10-27	2010-06-23	武田薬品工業株式会社	新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6528054B1 (en)	1998-12-28	2003-03-04	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
HK1047045A1 (zh)	1999-06-28	2003-02-07	Abbott Gmbh & Co. Kg	預防腫瘤生長的方法
US6638906B1 (en)	1999-12-13	2003-10-28	Nobex Corporation	Amphiphilic polymers and polypeptide conjugates comprising same
WO2001044469A1 (fr)	1999-12-17	2001-06-21	Takeda Chemical Industries, Ltd.	PROCEDE DE PRODUCTION DE PEPTIDE KiSS-1
JP2001231581A (ja) *	1999-12-17	2001-08-28	Takeda Chem Ind Ltd	ＫｉＳＳ−１ペプチドの製造法
HUP0500345A2 (hu)	2000-03-29	2005-07-28	Corixa Corporation	Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
CA2404257A1 (fr)	2000-03-30	2001-10-11	Takeda Chemical Industries, Ltd.	Nouvelle proteine, adn codant pour celle-ci, et son procede de production
US7834141B1 (en)	2000-03-31	2010-11-16	Theresa Siler-Khodr	Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru)	2000-09-20	2007-12-10	Корикса Корпорейшн	Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja)	2000-11-29	2003-01-29	Takeda Chem Ind Ltd	医薬組成物およびその製造法
JP2002320496A (ja)	2001-02-26	2002-11-05	Takeda Chem Ind Ltd	新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ
WO2002085399A1 (fr)	2001-04-20	2002-10-31	Takeda Chemical Industries, Ltd.	Preparations contenant un peptide
US20040185525A1 (en) *	2001-05-17	2004-09-23	Osamu Nishimura	Process for producing peptide
ATE360034T1 (de) *	2001-09-19	2007-05-15	Takeda Pharmaceutical	Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
EP1466976A4 (fr)	2002-01-11	2005-11-09	Takeda Pharmaceutical	Procede de production du peptide kiss-1
JP2003300906A (ja)	2002-04-12	2003-10-21	Daiichi Fine Chemical Co Ltd	がん転移抑制因子の安定化
US20060035875A1 (en)	2002-10-09	2006-02-16	Yukimasa Shiotsu	Remedy for hormone-dependent cancer
CA2503164A1 (fr)	2002-10-25	2004-05-06	Paradigm Therapeutics Limited	Mammiferes < inactives > gpr54 et procedes de criblage utilisantces ma mmiferes
JP4804714B2 (ja)	2002-12-26	2011-11-02	武田薬品工業株式会社	メタスチン誘導体およびその用途
AU2003292696A1 (en)	2002-12-26	2004-08-10	Takeda Pharmaceutical Company Limited	Metastin derivative and use thereof
US6800611B2 (en)	2003-01-06	2004-10-05	Takeda Chemical Industries, Ltd.	Metastin derivatives and their use
KR100595364B1 (ko)	2003-02-20	2006-07-03	재단법인 목암생명공학연구소	Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
EP1604682A4 (fr)	2003-03-12	2009-06-24	Takeda Chemical Industries Ltd	Agents ameliorant la fonction gonadique
EP1464652A1 (fr)	2003-04-02	2004-10-06	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Agoniste et antagoniste du récepteur GPR54 utiles pour le traitement des maladies associées à la gonadotrophine
US20050002935A1 (en)	2003-04-17	2005-01-06	Vincent Ling	Use of B7-H3 as an immunoregulatory agent
CA2523600A1 (fr)	2003-04-28	2004-11-11	Wyeth	Procedes et compositions permettant de moduler le recepteur 54 couple a une proteine g
WO2004101747A2 (fr)	2003-05-07	2004-11-25	The General Hospital Corporation	Identification et utilisation de gpr54 et de ses ligands pour les troubles de la reproduction et la contraception
US20070155803A1 (en)	2003-05-30	2007-07-05	Prozymex A/S	Protease inhibitors
JP4688678B2 (ja)	2003-11-03	2011-05-25	北京沙東生物技術有限公司	抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用
RU2333221C2 (ru)	2003-11-03	2008-09-10	Бейцзин Санбио Байотек Ко., Лтд.	Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
WO2005095973A2 (fr)	2004-03-25	2005-10-13	Bayer Healthcare Ag	Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
CA2562676A1 (fr)	2004-04-23	2005-12-15	Applied Research Systems Ars Holding N.V.	Utilisation de ligands gpcr54 pour le traitement de l'infertilite
MXPA06014206A (es)	2004-06-25	2007-02-14	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos.
WO2007084211A2 (fr)	2005-11-11	2007-07-26	The General Hospital Corporation	Utilisation de ligands du gpr54 pour le traitement de troubles de la reproduction, de troubles proliferatifs et pour la contraception
US20090099334A1 (en)	2005-12-22	2009-04-16	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20090093615A1 (en)	2005-12-22	2009-04-09	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
TWI386417B (zh)	2005-12-22	2013-02-21	Takeda Pharmaceutical	轉移抑素衍生物及其用途
US8404643B2 (en)	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
JP2009530379A (ja)	2006-03-20	2009-08-27	メルクエンドカムパニーインコーポレーテッド	ニューロメジンｕ受容体アゴニスト及びその使用
WO2007109857A1 (fr)	2006-03-28	2007-10-04	Biopharmica Ltd	Agent pour le traitement de troubles hormono-dépendants et utilisations de celui-ci
TWI404726B (zh)	2006-10-25	2013-08-11	Takeda Pharmaceutical	腫瘤轉移抑制素衍生物及其用途
WO2009044918A1 (fr)	2007-10-05	2009-04-09	Takeda Pharmaceutical Company Limited	Dérivé de neuromédine u
EP2277900A4 (fr)	2008-04-24	2011-08-03	Takeda Pharmaceutical	Dérivé de métastine et son utilisation
EP2340047A1 (fr)	2008-09-19	2011-07-06	Nektar Therapeutics	Conjugués de polymère de peptides kiss1

2005
- 2005-06-23 MX MXPA06014206A patent/MXPA06014206A/es unknown
- 2005-06-23 AU AU2005257484A patent/AU2005257484A1/en not_active Abandoned
- 2005-06-23 BR BRPI0512397-6A patent/BRPI0512397A/pt not_active IP Right Cessation
- 2005-06-23 RU RU2006145886/04A patent/RU2006145886A/ru not_active Application Discontinuation
- 2005-06-23 JP JP2006554374A patent/JP4346650B2/ja not_active Expired - Fee Related
- 2005-06-23 PE PE2005000728A patent/PE20060371A1/es not_active Application Discontinuation
- 2005-06-23 PE PE2009000637A patent/PE20091567A1/es not_active Application Discontinuation
- 2005-06-23 AR ARP050102591A patent/AR049938A1/es unknown
- 2005-06-23 WO PCT/JP2005/012021 patent/WO2006001499A2/fr not_active Ceased
- 2005-06-23 US US11/630,698 patent/US7625869B2/en not_active Expired - Fee Related
- 2005-06-23 SG SG200904360-5A patent/SG153865A1/en unknown
- 2005-06-23 EP EP09075257.7A patent/EP2113513B1/fr not_active Expired - Lifetime
- 2005-06-23 CN CN200910225194A patent/CN101863971A/zh active Pending
- 2005-06-23 TW TW094120917A patent/TW200607816A/zh unknown
- 2005-06-23 EP EP05755666A patent/EP1758932A2/fr not_active Withdrawn
- 2005-06-23 NZ NZ552029A patent/NZ552029A/en not_active IP Right Cessation
- 2005-06-23 CA CA002571420A patent/CA2571420A1/fr not_active Abandoned
- 2005-06-23 CN CN200910225195A patent/CN101845091A/zh active Pending
2006
- 2006-11-27 IL IL179640A patent/IL179640A0/en unknown
- 2006-12-21 NO NO20065957A patent/NO20065957L/no not_active Application Discontinuation
- 2006-12-22 CR CR8828A patent/CR8828A/es not_active Application Discontinuation
- 2006-12-28 MA MA29567A patent/MA28903B1/fr unknown
2008
- 2008-09-25 JP JP2008245073A patent/JP4654284B2/ja not_active Expired - Fee Related
- 2008-10-01 US US12/286,671 patent/US8778871B2/en active Active
- 2008-12-15 CL CL2008003730A patent/CL2008003730A1/es unknown
2009
- 2009-06-01 JP JP2009132363A patent/JP2009227687A/ja active Pending

Also Published As

Publication number	Publication date
US8778871B2 (en)	2014-07-15
SG153865A1 (en)	2009-07-29
US7625869B2 (en)	2009-12-01
MXPA06014206A (es)	2007-02-14
CN101845091A (zh)	2010-09-29
EP2113513A2 (fr)	2009-11-04
BRPI0512397A (pt)	2008-03-04
CR8828A (es)	2007-07-19
PE20060371A1 (es)	2006-06-15
JP2009227687A (ja)	2009-10-08
EP2113513B1 (fr)	2016-05-18
WO2006001499A2 (fr)	2006-01-05
NO20065957L (no)	2007-01-25
US20080312155A1 (en)	2008-12-18
AU2005257484A1 (en)	2006-01-05
PE20091567A1 (es)	2009-11-03
JP4654284B2 (ja)	2011-03-16
RU2006145886A (ru)	2008-06-27
AR049938A1 (es)	2006-09-13
WO2006001499A3 (fr)	2006-03-02
JP2009024028A (ja)	2009-02-05
US20090298765A1 (en)	2009-12-03
TW200607816A (en)	2006-03-01
IL179640A0 (en)	2007-05-15
EP2113513A3 (fr)	2010-11-03
NZ552029A (en)	2009-01-31
JP2008506632A (ja)	2008-03-06
CN101863971A (zh)	2010-10-20
EP1758932A2 (fr)	2007-03-07
CA2571420A1 (fr)	2006-01-05
JP4346650B2 (ja)	2009-10-21
MA28903B1 (fr)	2007-10-01

Publication	Publication Date	Title
CY1125550T1 (el)	2026-02-25	Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
CL2011000124A1 (es)	2011-05-06	Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2008002243A1 (es)	2009-08-21	Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CY1116929T1 (el)	2017-04-05	Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
EA201001143A1 (ru)	2011-02-28	Активаторы прокаспаз "исполнителей" 3, 6 и 7
WO2006123113A3 (fr)	2007-01-04	Composes chimiques
CR10072A (es)	2008-08-25	Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NZ577916A (en)	2012-11-30	Cyclopamine analogs
MX346924B (es)	2017-04-05	Compuestos de diarilhidantoina.
DK1853602T3 (da)	2010-09-20	Kemiske forbindelser
CY1108275T1 (el)	2014-02-12	Χημικες ενωσεις
EA201101650A1 (ru)	2012-07-30	Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
CL2011003082A1 (es)	2012-06-08	Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
CL2008000020A1 (es)	2009-01-23	Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
EA200801362A1 (ru)	2009-02-27	Пиримидинил бензотиофеновые соединения
MY149512A (en)	2013-09-13	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
UY32882A (es)	2011-04-29	(heteroarilmetil) tiohidantoínas sustituidas
CL2007002382A1 (es)	2008-01-18	Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
CL2008000021A1 (es)	2009-03-27	Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
EA201100126A1 (ru)	2011-08-30	Нафтиридиноны в качестве ингибиторов протеинкиназ
NZ594186A (en)	2012-12-21	Indole derivatives as anticancer agents
EA201170344A1 (ru)	2011-08-30	Азаиндольные ингибиторы iap
UY29414A1 (es)	2006-10-02	Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201071307A1 (ru)	2011-06-30	Карбамоильные производные бициклических карбониламинопиразолов в качестве пролекарств
MX2009011822A (es)	2010-01-14	Hidroxi sulfonatos de compuestos de quinonicos y sus usos.